Literature DB >> 10454208

CK2: a protein kinase in need of control.

B Guerra1, B Boldyreff, S Sarno, L Cesaro, O G Issinger, L A Pinna.   

Abstract

Protein kinase CK2 is a heterotetrameric alpha2beta2 Ser/Thr protein kinase with some features unusual among the eukaryotic protein kinases: (1) CK2 recognizes phosphoacceptor sites specified by several acidic determinants; (2) CK2 can use both ATP and GTP as phosphoryl donors; and (3) the regulatory properties of CK2 are poorly understood; it is insensitive to any known second messenger and displays high basal activity. To gain insight into CK2 regulation and to understand its unusual properties, site-directed mutagenesis experiments on both subunits and X-ray crystallographic studies of the catalytic alpha-subunit were performed. The noncatalytic beta-subunit has at least three functions: (1) it protects the alpha-subunit against denaturing agents or conditions; (2) it alters the substrate specificity of the alpha-subunit; and (3) it modulates the activity of the enzyme, i.e., depending on the substrate, it increases or decreases the activity of the alpha-subunit. Mutagenesis experiments revealed that an acidic stretch between amino acids 55 and 64 has a down-regulatory and autoinhibitory function. Mutational analysis of the alpha-subunit has revealed a network of unique basic residues that are responsible for the recognition of phosphoacceptor substrates and for down-regulation by the beta-subunit and by polyanionic inhibitors. The resolution of the crystal structure of Zea mays CK2 alpha-subunit has disclosed the structural features that are responsible for high basal activity and for unusual response to nucleotide analogs. The increasing knowledge of CK2 structure-function relationships will allow the design of highly selective inhibitors of this pleiotropic kinase with oncogenic potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454208     DOI: 10.1016/s0163-7258(98)00064-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  33 in total

Review 1.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

Authors:  W Kolch
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II).

Authors:  Y Zhou; W Gross; S H Hong; M L Privalsky
Journal:  Mol Cell Biochem       Date:  2001-04       Impact factor: 3.396

3.  Distinctive features of plant protein kinase CK2.

Authors:  M Riera; G Peracchia; M Pagès
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

4.  HIV-1 Rev transactivator: a beta-subunit directed substrate and effector of protein kinase CK2.

Authors:  F Meggio; O Marin; M Boschetti; S Sarno; L A Pinna
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

5.  Isolation of a CK2α subunit and the holoenzyme from the mussel Mytilus galloprovincialis and construction of the CK2α and CK2β cDNAs.

Authors:  Regina-Maria Kolaiti; Andrea Baier; Ryszard Szyszka; Sophia Kouyanou-Koutsoukou
Journal:  Mar Biotechnol (NY)       Date:  2010-10-05       Impact factor: 3.619

6.  DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells.

Authors:  S R Mullapudi; F Ali-Osman; J Shou; K S Srivenugopal
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

7.  Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK.

Authors:  Ferdinand Kappes; Catalina Damoc; Rolf Knippers; Michael Przybylski; Lorenzo A Pinna; Claudia Gruss
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

9.  CK2 interacting proteins: emerging paradigms for CK2 regulation?

Authors:  Mary Ellen K Olsten; Jane E Weber; David W Litchfield
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

10.  Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37.

Authors:  Yoshihiko Miyata; Eisuke Nishida
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.